Expansion of antileukaemia CTL lines and clones for adoptive cell therapy in paediatric patients given allogeneic haematopoietic stem cell transplantation

Research output: Contribution to journalArticle

Abstract

Recurrence of the original disease remains the main cause of treatment failure in patients given allogeneic haematopoietic stem cell transplantation for either acute or chronic leukaemia. Infusion of donor lymphocytes (DLI) is useful for rescuing patients with chronic myeloid leukaemia, while this option is of limited value in patients with acute leukaemia. Moreover, DLI may cause fatal graft-versus-host disease (GvHD) or prolonged myelosuppression. A more sophisticated approach is that of generating and expanding ex vivo T-cell lines or clones able to selectively or preferentially lyse leukaemia blasts, while sparing non neoplastic targets. In this review, we will summarize the results we have obtained in vitro utilizing an approach based on the generation of leukaemia reactive cytotoxic T-lymphocytes through the use of apoptotic leukaemia cells as source of tumor antigens. Our approach proved to be feasible and effective in the experimental model for different types of leukaemia, even when the donor was HLA-disparate with the recipient. This strategy has to be tested in the clinical setting for proving its efficacy in preventing/treating leukaemia recurrence.

Original languageEnglish
Pages (from-to)389-393
Number of pages5
JournalInternational Journal of Immunogenetics
Volume35
Issue number4-5
DOIs
Publication statusPublished - Aug 2008

Fingerprint

Hematopoietic Stem Cell Transplantation
Cell- and Tissue-Based Therapy
Leukemia
Clone Cells
Pediatrics
Tissue Donors
Recurrence
Cytotoxic T-Lymphocytes
Neoplasm Antigens
Graft vs Host Disease
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Treatment Failure
Theoretical Models
Lymphocytes
T-Lymphocytes
Cell Line

ASJC Scopus subject areas

  • Genetics
  • Molecular Biology
  • Immunology
  • Genetics(clinical)

Cite this

@article{ebe6935e4ccb40a98c181dfd1ce50ff5,
title = "Expansion of antileukaemia CTL lines and clones for adoptive cell therapy in paediatric patients given allogeneic haematopoietic stem cell transplantation",
abstract = "Recurrence of the original disease remains the main cause of treatment failure in patients given allogeneic haematopoietic stem cell transplantation for either acute or chronic leukaemia. Infusion of donor lymphocytes (DLI) is useful for rescuing patients with chronic myeloid leukaemia, while this option is of limited value in patients with acute leukaemia. Moreover, DLI may cause fatal graft-versus-host disease (GvHD) or prolonged myelosuppression. A more sophisticated approach is that of generating and expanding ex vivo T-cell lines or clones able to selectively or preferentially lyse leukaemia blasts, while sparing non neoplastic targets. In this review, we will summarize the results we have obtained in vitro utilizing an approach based on the generation of leukaemia reactive cytotoxic T-lymphocytes through the use of apoptotic leukaemia cells as source of tumor antigens. Our approach proved to be feasible and effective in the experimental model for different types of leukaemia, even when the donor was HLA-disparate with the recipient. This strategy has to be tested in the clinical setting for proving its efficacy in preventing/treating leukaemia recurrence.",
author = "D. Montagna and R. Maccario and F. Locatelli",
year = "2008",
month = "8",
doi = "10.1111/j.1744-313X.2008.00797.x",
language = "English",
volume = "35",
pages = "389--393",
journal = "International Journal of Immunogenetics",
issn = "1744-3121",
publisher = "Wiley-Blackwell",
number = "4-5",

}

TY - JOUR

T1 - Expansion of antileukaemia CTL lines and clones for adoptive cell therapy in paediatric patients given allogeneic haematopoietic stem cell transplantation

AU - Montagna, D.

AU - Maccario, R.

AU - Locatelli, F.

PY - 2008/8

Y1 - 2008/8

N2 - Recurrence of the original disease remains the main cause of treatment failure in patients given allogeneic haematopoietic stem cell transplantation for either acute or chronic leukaemia. Infusion of donor lymphocytes (DLI) is useful for rescuing patients with chronic myeloid leukaemia, while this option is of limited value in patients with acute leukaemia. Moreover, DLI may cause fatal graft-versus-host disease (GvHD) or prolonged myelosuppression. A more sophisticated approach is that of generating and expanding ex vivo T-cell lines or clones able to selectively or preferentially lyse leukaemia blasts, while sparing non neoplastic targets. In this review, we will summarize the results we have obtained in vitro utilizing an approach based on the generation of leukaemia reactive cytotoxic T-lymphocytes through the use of apoptotic leukaemia cells as source of tumor antigens. Our approach proved to be feasible and effective in the experimental model for different types of leukaemia, even when the donor was HLA-disparate with the recipient. This strategy has to be tested in the clinical setting for proving its efficacy in preventing/treating leukaemia recurrence.

AB - Recurrence of the original disease remains the main cause of treatment failure in patients given allogeneic haematopoietic stem cell transplantation for either acute or chronic leukaemia. Infusion of donor lymphocytes (DLI) is useful for rescuing patients with chronic myeloid leukaemia, while this option is of limited value in patients with acute leukaemia. Moreover, DLI may cause fatal graft-versus-host disease (GvHD) or prolonged myelosuppression. A more sophisticated approach is that of generating and expanding ex vivo T-cell lines or clones able to selectively or preferentially lyse leukaemia blasts, while sparing non neoplastic targets. In this review, we will summarize the results we have obtained in vitro utilizing an approach based on the generation of leukaemia reactive cytotoxic T-lymphocytes through the use of apoptotic leukaemia cells as source of tumor antigens. Our approach proved to be feasible and effective in the experimental model for different types of leukaemia, even when the donor was HLA-disparate with the recipient. This strategy has to be tested in the clinical setting for proving its efficacy in preventing/treating leukaemia recurrence.

UR - http://www.scopus.com/inward/record.url?scp=52649135451&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=52649135451&partnerID=8YFLogxK

U2 - 10.1111/j.1744-313X.2008.00797.x

DO - 10.1111/j.1744-313X.2008.00797.x

M3 - Article

C2 - 18976444

AN - SCOPUS:52649135451

VL - 35

SP - 389

EP - 393

JO - International Journal of Immunogenetics

JF - International Journal of Immunogenetics

SN - 1744-3121

IS - 4-5

ER -